Identity:


Title: M.D., Ph.D., FHFA Family Name(s): Chaloupka

First Name(s): Anna

Age: 37

Application for the following position in the HFA Board or Nominating Committee:

Ordinary Board member



Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

,	1
Institute/organisation:	St. Anne's University Hospital Brno
Department:	Cardiology
Address:	Pekarska 53, Brno
Post code / Zip:	602 00
Country:	Czech Republic

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Personal Statement

With my career dedicated to the advancement of cardiology, particularly heart failure and inherited cardiac conditions, I am honored to present my candidacy for the Board of the Heart Failure Association. My professional journey is characterized by a commitment to clinical excellence, groundbreaking research, and leadership in cardiology across prestigious institutions in the Czech Republic, United States of America and the United Kingdom. This journey reflects my dedication to improving patient care, fostering innovation in treatment methodologies, and mentoring the next generation of medical professionals. I am driven by a vision to integrate cutting-edge research and clinical practices to elevate global patient care standards, and I am eager to contribute my expertise to the esteemed mission of the Heart Failure Association.

Curriculum Vitae Narrative

Currently, I serve as a Consultant Cardiologist and the Lead of the Inherited Cardiac Conditions Clinic at St. Anne's University Hospital in Brno, Czech Republic, where I oversee a multidisciplinary team dedicated to advancing the care of patients with inherited cardiac conditions. Additionally, I hold an Honorary Consultant position at Guy's and St. Thomas' NHS Foundation Trust in London, U.K., and contribute to the academic community as an Assistant Professor at the Faculty of Medicine, Masaryk University in Brno. My role as the Founder and CEO of the Czech Cardiomyopathy Charity underscores my commitment to supporting cardiomyopathy research and patient care. Furthermore, as the ESC Heart Failure Association Young Ambassador for Czechia, I am deeply involved in promoting heart failure awareness and education.

My professional qualifications are underpinned by full specialist registrations in cardiology in both the U.K. and the Czech Republic, alongside ESC certifications in adult transthoracic echocardiography and heart failure. My academic foundation is solid, with a Ph.D. in General Medicine – Cardiology from Masaryk University (2018), where my research focused on the pathophysiology and therapy of heart failure, and a medical degree from the same institution (2011).

Throughout my career, I have been recognized for my contributions to cardiology with awards such as the Masaryk University Specific Research Grant (2023) and the prestigious fellowship of the Heart Failure Association of ESC (2019). My research endeavors have taken me to renowned institutions such as Harvard Medical School (2014) and the Mayo Clinic (2011), where I focused on basic research in cardiomyopathy and heart failure. To deepen my knowledge and skills in the field of Inherited Cardiac Conditions, I have then trained as Senior Clinical Fellow at Guy's and St. Thomas' NHS Foundation Trust in London, U.K. (2018/2019) before returning back to Czech Republic to set up a new Cardiomyopathy service in my home institution.

As a clinician, I have led the Inherited Cardiac Conditions Clinic and managed a COVID-19 ward during the pandemic, showcasing my adaptability and leadership. My academic roles include teaching and supervising Ph.D. students at Masaryk University, further demonstrating my commitment to education and mentorship.

In conclusion, my career is a testament to my dedication to cardiology, marked by clinical leadership, innovative research, and a deep commitment to patient care and education. I am passionate about bringing my experience and vision to the Heart Failure Association, aiming to contribute significantly to its mission and to the advancement of global heart failure care.

H-index WoS: 2 Publications:

- Liu D, Wang M, Murthy V, McNamara DM, Nguyen TTL, Philips TJ, Vyas H, Gao H, Sahni J, Starling RC, Cooper LT, Skime MK, Batzler A, Jenkins GD, Barlera S, Pileggi S, Mestroni L, Merlo M, Sinagra G, Pinet F, Krejčí J, Chaloupka A, Miller JD, de Groote P, Tschumperlin DJ, Weinshilboum RM, Pereira NL. Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis. Circ Res. 2023 Oct 27;133(10):810-825. doi: 10.1161/CIRCRESAHA.123.323200. Epub 2023 Oct 6. PMID: 37800334; PMCID: PMC10746262.
- Mayerova L, Chaloupka A, Wohlfahrt P, Hubacek JA, Bedanova H, Chen Z, Kautzner J, Melenovsky V, Malek I, Tomasek A, Ozabalova E, Krejci J, Kovarnik T, Sonka M, Pazdernik M. Role of genetics in the development of cardiac allograft vasculopathy. Bratisl Lek Listy. 2023;124(3):193-200. doi: 10.4149/BLL_2023_031. PMID: 36598310; PMCID: PMC10517863.
- 3. Georgiopoulos G, Zampieri M, Molaro S, Chaloupka A, Aimo A, Barra B, Roberts L, Monje-Garcia L, Evans C, Sheikh N, Bastiaenen R, Cooklin M, Masci PG, Carr-White G, Finocchiaro G, Chiribiri A. Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. Int J Cardiovasc Imaging. 2021 Jun;37(6):2037-2047. doi: 10.1007/s10554-021-02166-7. Epub 2021 Feb 7. PMID: 33550486; PMCID: PMC8255264.
- 4. Gurka J, Piherova L, Majer F, Chaloupka A, Zakova D, Pelak O, Krebsova A, Peichl P, Krejci J, Freiberger T, Melenovsky V, Kautzner J, Kalina T, Sikora J, Kubanek M. Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study. ESC Heart Fail. 2020 Oct;7(5):2534-2543. doi: 10.1002/ehf2.12823. Epub 2020 Jul 13. PMID: 32657043; PMCID: PMC7524080.

5

6. Ch Poloczková H, Honek T, Chaloupka A, Opatřil L, Bakošová M, Krejčí J. News in diagnostics and treament of cardiomyopathies. Vnitr Lek. 2023 Spring;69(2):89-104. English. doi:

10.36290/vnl.2023.016. PMID: 37072267. aloupka A, Piherova L, Grochova I, Binova J, Krejci J, Spinarova L, Stranecky V, Kmoch S, Kubanek M. Genetic architecture of recent-onset dilated cardiomyopathy in Moravian region assessed by whole-exome sequencing and its clinical correlates. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Dec;163(4):309-317. doi: 10.5507/bp.2018.054. Epub 2018 Sep 24. PMID: 30275597.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society 150 words maximum

Within the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), I have proudly served as the Young Ambassador for Czechia for two consecutive terms now. My involvement has been instrumental in promoting educational initiatives, raising awareness about heart failure, and facilitating international collaboration. I have been actively involved in the Heart Failure Awareness Days, preparing posters and educational events and my poster has been awarded by the HFA in 2021.

Additionally, my contributions to the Czech Society of Cardiology, particularly as a Board Member of the Heart Failure Association (2023-present) and Kardio35 (2019-present), underscore my commitment to advancing heart failure and education at a national level. These roles have enabled me to engage with leading experts in the field, contribute to policy discussions, and advocate for patient-centered care. My experience within these prestigious organizations reflects a deep dedication to the cardiology community and a continuous effort to enhance heart failure management and outcomes.

Why are you motivated to join the HFA Board or Nominating Committee? 150 words maximum

My motivation to join the HFA Board stems from a deep-seated commitment to advancing the field of heart failure, a passion that has been the cornerstone of my career. Having served as the ESC Heart Failure Association Young Ambassador for Czechia and contributed significantly to both the European and Czech cardiac societies, I am eager to leverage my experience, insights, and leadership skills at a higher strategic level. Joining the Board would enable me to contribute more effectively to shaping the future of heart failure care and research, fostering international collaboration, and promoting innovative practices that can transform patient outcomes. I am particularly driven by the opportunity to influence policy, advocate for the integration of cuttingedge research into clinical practice, and mentor the next generation of cardiologists. My goal is to ensure that the HFA continues to lead in the global effort to combat heart failure, enhancing both its visibility and impact.

How will you combine your HFA position with your daily clinical/research workload? 80 words maximum

Leveraging my current roles as a consultant cardiologist, researcher, and educator, I plan to integrate my HFA responsibilities seamlessly into my daily activities. My experience in managing multidisciplinary teams and leading clinical research projects has honed my ability to prioritize

effectively and multitask. I will utilize these skills to ensure that my contributions to the HFA are impactful, while maintaining excellence in my clinical and research duties. Collaborative support from my team at the university and hospital will further facilitate this balance.